Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pharmarise Holdings Corp. (2796:JPX), powered by AI.
Pharmarise Holdings Corp. is currently trading at ¥498. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Pharmarise Holdings Corp. on Alpha Lenz.
Pharmarise Holdings Corp.'s P/E ratio is -15.3.
“Pharmarise Holdings Corp. trades at a P/E of -15.3 (undervalued) with modest ROE of -5.2%.”
Ask for details →Pharmarise Holdings Corp. operates as a healthcare and pharmaceutical company, predominantly engaged in the management of pharmacies across Japan. The primary function of Pharmarise Holdings Corp. is to provide comprehensive pharmaceutical services, including the dispensing of medications, health consultations, and pharmaceutical management. As a leading player in the health services sector, the company strives to enhance community wellness by improving access to necessary medicines and offering professional healthcare advice. Pharmarise Holdings Corp. significantly impacts the healthcare industry by ensuring that communities receive timely and accurate pharmaceutical care. By operating a network of pharmacies, the company plays a critical role in the retail pharmaceutical market, aiding in the distribution of prescription and over-the-counter medications. Pharmarise Holdings Corp.’s market role is vital as it enhances the quality of healthcare delivery within its operational regions, contributing to the overall health infrastructure. As part of the wider healthcare system in Japan, the company has established a significant presence, enabling it to influence patient care standards and pharmacy operations effectively.
“Pharmarise Holdings Corp. trades at a P/E of -15.3 (undervalued) with modest ROE of -5.2%.”
Ask for details →Pharmarise Holdings Corp. (ticker: 2796) is a company listed on JPX in the Healthcare sector (Pharmaceutical Retailers). It has approximately 2,039 employees. Market cap is $5.6B.
The current price is 498 with a P/E ratio of -15.32x and P/B of 0.82x.
ROE is -5.17% and operating margin is 0.46%. Annual revenue is $63.5B.